Qihan Raises $20 Million for Gene Editing to Enable Xenotransplants
publication date: Jul 25, 2019
Qihan Biotech, a Hangzhou startup, raised $20 million in a B round to advance its use of CRISPR Cas-9 gene editing to allow xenotransplantation, the use of animal organs as transplants. The round was led by CMB International and Legend Star. Qihan's goal is to remedy the global shortage of human organs for transplants. The company was founded by the chief scientist of eGenesis, Luhan Yang, PhD, and Harvard professor George Church, PhD. eGenesis is also focused on the use of CRISPR Cas-9 gene editing to enable xenotransplantation. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.